<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346872</article-id>
      <article-id pub-id-type="pmc">3875971</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132487</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab - a
paradoxical effect? A case report<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Agravamento de les&#xF5;es refrat&#xE1;rias de sarcoidose cut&#xE2;nea com adalimumab-
um efeito paradoxal? Relato de um caso</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Guida</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sousa</surname>
            <given-names>Lourdes Emerenciano</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jo&#xE3;o</surname>
            <given-names>Alexandre Miguel Bruno Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, Resident at the Dermatolovenereology Department of the Santo
Ant&#xF3;nio dos Capuchos Hospital - Centro Hospitalar de Lisboa Central -Lisbon.</aff>
      <aff id="aff02"><label>2</label> MD Consultant at S&#xE3;o Bernardo Hospital - Centro Hospitalar de Set&#xFA;bal,
EPE - Set&#xFA;bal, Portugal.</aff>
      <aff id="aff03"><label>3</label> MD Consultant at Santo Ant&#xF3;nio dos Capuchos Hospital - Centro
Hospitalar de Lisboa Central - Lisbon, Portugal.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Guida Santos, Department of Dermatology and
Venereology, Hospital Santo Ant&#xF3;nio dos Capuchos, Alameda Santo Ant&#xF3;nio dos Capuchos,
1169-050 - Lisbon, Portugal. E-mail: <email>guidadossantos@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>26</fpage>
      <lpage>28</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>1</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha)
antagonists have been described frequently as a result of the widespread use of these
drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of
adalimumab in cutaneous sarcoidosis, although all of them show good results. More
recently, sarcoidosis onsets have been reported with various TNF-alpha inhibitors.
The current case is, to our knowledge, the first to describe the exacerbation of
cutaneous lesions of sarcoidosis treated with adalimumab.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Os efeitos paradoxais dos anti-TNF-alpha t&#xEA;m sido cada vez mais descritos com a
utiliza&#xE7;&#xE3;o mais ampla dessas drogas. Entre os TNF-alpha, registam-se poucos casos com
a utiliza&#xE7;&#xE3;o de adalimumab no tratamento da sarcoidose cut&#xE2;nea, sendo que todos eles
apresentam bons resultados. T&#xEA;m sido descritos, mais recentemente, casos de
sarcoidose induzidos por v&#xE1;rios anti-TNF-alpha. O presente caso &#xE9;, at&#xE9; &#xE0; data, o
primeiro a descrever a exacerba&#xE7;&#xE3;o de les&#xF5;es cut&#xE2;neas de sarcoidose tratadas com
adalimumab.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Biological agents</kwd>
        <kwd>Biological treatment</kwd>
        <kwd>Sarcoidosis</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Sarcoidosis is a multisystemic inflammatory disorder of unknown cause<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref></sup>
and for which there is no universally accepted treatment. Systemic agents such as
corticosteroids are often effective, and steroid-sparing agents such as methotrexate,
azathioprine, antimalarial drugs, pentoxifylline, allopurinol and thalidomide have been
shown to be beneficial for selected patients, but their use is limited due to
significant toxic effects of their own and inconsistencies in efficacy.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Refractory systemic and cutaneous
sarcoidosis has been shown to improve with inhibition of TNF- &#x3B1;. Few reports are
available with adalimumab in the treatment of cutaneous sarcoidosis. With the widespread
use of TNF-&#x3B1; antagonists, paradoxical adverse effects have been described more
frequently with these drugs and are defined as the onset or exacerbation of disorders
that are usually improved by their administration.<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup> Psoriasis onset or
exacerbation and sarcoid-like-granulomatosis onset has been more frequently reported
with TNF-&#x3B1; inhibitors, but rare cases of exacerbation of cutaneous sarcoidosis have been
documented with them.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup>
</p>
      <p>The authors describe a clinical case of cutaneous sarcoidosis in which the treatment
with adalimumab was not only ineffective, but exacerbation of the disease was
observed.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 50-year-old female was observed due to erythematous, infiltrated, sometimes ulcerated
plaques, on the frontal and left preauricular areas lasting for 2 years. (<xref ref-type="fig" rid="f01">Figure 1</xref>). The patient had high blood pressure and
was treated with bisoprolol 5mg/day.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>
<bold>(A)</bold> Plaque of sarcoidosis on the frontal area and <bold>(B)</bold> on
the left preauricular area just before adalimumab; <bold>(C)</bold> Plaque on the
frontal area and <bold>(D)</bold> on the left preauricular area after 3 injections
of adalimumab</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0026-g01"/>
      </fig>
      <p>The plaque on the left preauricular area was biopsied. Biopsy was performed showing
dermal granuloma, without central caseous necrosis and numerous Langhans multinucleated
giant cells. (<xref ref-type="fig" rid="f02">Figure 2</xref>) Acid-fast bacteria stains
were negative as well as tissue cultures for mycobacteria, bacteria and fungi.
Infectious etiology was excluded and the diagnosis of cutaneous sarcoidosis was made.
Except for cutaneous involvement, the patient was in good health with no systemic
symptoms. Further evaluations included a complete blood cell count and complete
metabolic panel, both of which revealed no significant abnormal findings.
C-reactive-protein, angiotensin-converting-enzyme (ACE) and calcium were in the normal
range. Further investigation for systemic involvement was negative. Local therapy with
topical and intralesional corticosteroids (momethasone furoate and clobetasol propionate
creams; betamethasone dipropionate and betamethasone phosphate sodium aqueous
suspension, successively) and topical tacrolimus failed. Hydroxychloroquine sulfate (400
mg daily), pentoxifylline (400 mg daily), methylprednisolone (up to 25 mg daily),
azathioprine (100 mg daily) and methotrexate (up to 27,5 mg /week until cumulative dosis
of 733 mg) produced no significant effect. </p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Histopathology H&amp;Ex200. Sarcoid granuloma in the reticular dermis (with
epithelioid hystiocytes, Langhans giant cells, without necrosis and some
peripheral lymphocytes)</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0026-g02"/>
      </fig>
      <p>Long-term treatment with systemic corticosteroids, azathioprine or methotrexate was felt
to be unwarranted because of the risk of serious long-term sequelae. Treatment with
adalimumab was proposed as an alternative to treatment with methotrexate. </p>
      <p>Tuberculin skin test was performed before initiating the biological agent and revealed a
1.1 millimeter papule. Therefore isoniazid (300mg/day) was started. </p>
      <p>Methotrexate was gradually tapered to 7.5 mg/week and methylprednisolone (4 mg/day) and
then stopped. Adalimumab (40 mg subcutaneously at week 1, 3 and 5) was started two
months after the start of isoniazid. Adalimumab was then suspended (after the third
injection) because the lesions became more erythematous, infiltrated, ulcerated and
associated to retroauricular adenopathies (<xref ref-type="fig" rid="f01">Figure
1</xref>). Shortly after suspension, the lesions improved. </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Effective management of patients with sarcoidosis remains problematic. Recent clinical
trials of TNF-&#x3B1; inhibitors for the treatment of sarcoidosis have reported mixed
results.<sup><xref ref-type="bibr" rid="r02">2</xref></sup> Anti-TNF-&#x3B1; blockers
appear to be effective in the manifestations of refractory sarcoidosis but they are not
approved by the FDA for the treatment of sarcoidosis. A survey of the available
literature revealed only 6 articles which report treatment of cutaneous sarcoidosis with
adalimumab and all these reports revealed good results.<sup><xref ref-type="bibr" rid="r05">5</xref>-<xref ref-type="bibr" rid="r10">10</xref></sup> These reports
showed adalimumab efficacy in different clinical settings, including leg ulcer,
cutaneous nodules and plaques on the face and lupus pernio. Three patients were treated
previously with another anti-TNF-&#x3B1; (1 etanercept and 2 infliximab).<sup><xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r07">7</xref></sup> Switching to another blocker resulted in
clinical improvement, which indicates that the granulomatosis occurrence is not
predictable. The pathogenesis of worsening of sarcoidosis as the induction of
sarcoid-like granuloma under these blockers is still not well understood. Disease
heterogeneity and differences in pharmacokinetics, pharmacodynamics and mechanisms of
action may account for these effects. </p>
      <p>A growing number of reports concerning paradoxical adverse events due to TNF-alpha
antagonists have been published.<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup> Most of the information available comes
from isolated clinics cases or small series of cases. </p>
      <p>There are more than 42 paradoxical effects of sarcoidoid-like granuloma during
anti-TNF-&#x3B1; therapy.<sup><xref ref-type="bibr" rid="r03">3</xref></sup> Non-exclusively
cutaneous involvement was more frequent. The suggested role of TNF-alpha in the genesis
of granulomas has led researchers to investigate anti-TNF-alpha treatment of granuloma
formation diseases. </p>
      <p>Genetic variations of the TNF-&#x3B1; gene is emerging as an important factor in determining
sarcoidosis predisposition and course. Polymorphism of the genes that mediate cytokine
production may be associated with distinct immune pathways, but implications of
TNF-alpha genes and the predisposition to resistance to therapy are still not known. </p>
      <p>Only a fraction of the treated population normally responds to biologics, and clinical
markers for the prediction of the efficacy are seldom available.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>In our case, although methylprednisolone was stopped and methotrexate slightly tapered,
this suggests a possible triggering role of the anti-TNF-&#x3B1; therapy because of the prompt
clinical improvement after discontinuation of adalimumab. </p>
      <p>Paradoxical effects of TNF-alpha blockers in sarcoidosis are based on the supposed
efficacy of these agents in this disease.<sup><xref ref-type="bibr" rid="r02">2</xref></sup> The worsening of the patient's lesions with adalimumab contributes to
the reports of paradoxical adverse events during TNF-&#x3B1; blocking agents. </p>
      <p>To our knowledge, our case is the first paradoxical exacerbation with adalimumab and the
third case to describe worsening of pre-existing cutaneous sarcoidosis with an
anti-TNF-alpha antagonist. A better understanding of the pathogenic role of TNF-&#x3B1; in
sarcoidosis and of its therapeutic blocking action will help to explain this phenomenon.
The development of pharmacogenomics to identify responders or non-responders is highly
desirable.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Work performed at the Department of Dermatology and Venereology of the Santo
Ant&#xF3;nio dos Capuchos Hospital - Centro Hospitalar de Lisboa Central - Porto,
Portugal.</p>
      </fn>
      <fn id="fn02" fn-type="financial-disclosure">
        <p>Financial support: none.</p>
      </fn>
      <fn id="fn03" fn-type="conflict">
        <p>Conflict of interests: none.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daldon</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Arruda</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>Noninfectious granulomas: sarcoidosis</article-title>
          <source>An Bras Dermatol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>559</fpage>
          <lpage>571</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Viguier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Richette</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bachelez</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wendling</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aubin</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Paradoxical adverse effects of anti-TNF-alpha treatmentonset or
exacerbation of cutaneous disorders</article-title>
          <source>Expert Rev Clin Immunol</source>
          <year>2009</year>
          <volume>5</volume>
          <fpage>421</fpage>
          <lpage>431</lpage>
          <pub-id pub-id-type="pmid">20477038</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Javot</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Scala-Bertola</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Massy</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Trenque</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Baldin</surname>
              <given-names>B</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Sarco&#xEF;dosis and anti-TNFa paradoxical class effect? Analysis of the
French Pharmacovigilance System database and literature review</article-title>
          <source>Therapie</source>
          <year>2011</year>
          <volume>66</volume>
          <fpage>149</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="pmid">21635863</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhaille</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Viseux</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Caudron</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dadban</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tribout</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Boumier</surname>
              <given-names>P</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment:
report of two cases</article-title>
          <source>Dermatology</source>
          <year>2010</year>
          <volume>220</volume>
          <fpage>234</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="pmid">20185892</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Callejas-Rubio</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez-P&#xE9;rez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ortego-Centeno</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor-alpha inhibitor treatment for
sarcoidosis</article-title>
          <source>Ther Clin Risk Manag</source>
          <year>2008</year>
          <volume>4</volume>
          <fpage>1305</fpage>
          <lpage>1313</lpage>
          <pub-id pub-id-type="pmid">19337437</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thielen</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Barde</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Saurat</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Laffitte</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Refractory chronic cutaneous sarcoidosis responsive to dose escalation
of TNF-alpha antagonists</article-title>
          <source>Dermatology</source>
          <year>2009</year>
          <volume>219</volume>
          <fpage>59</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">19468200</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Field</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Regan</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Sheahan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to
etanercept</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>795</fpage>
          <lpage>796</lpage>
          <pub-id pub-id-type="pmid">20831604</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Judson</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Successful treatment of lupus pernio with adalimumab</article-title>
          <source>Arch Dermatol</source>
          <year>2011</year>
          <volume>147</volume>
          <fpage>1332</fpage>
          <lpage>1333</lpage>
          <pub-id pub-id-type="pmid">22106129</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaiser</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Cozzio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hofbauer</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Kamarashev</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>French</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Navarini</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Disfiguring annular sarcoidosis improved by adalimumab</article-title>
          <source>Case Rep Dermatol</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>103</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="pmid">21677887</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Philips</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Azmi</surname>
              <given-names>FH</given-names>
            </name>
          </person-group>
          <article-title>Ulcerative cutaneous sarcoidosis responding to
adalimumab</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2005</year>
          <volume>53</volume>
          <fpage>917</fpage>
          <lpage>917</lpage>
          <pub-id pub-id-type="pmid">16243166</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
